ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.50.

ALXO has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, December 18th. Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and lowered their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research note on Wednesday, December 18th.

Insider Buying and Selling

In other news, Director Rekha Hemrajani purchased 30,000 shares of the stock in a transaction on Monday, December 2nd. The stock was bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 33.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ALX Oncology

Several institutional investors have recently modified their holdings of ALXO. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares in the last quarter. Rhumbline Advisers raised its position in shares of ALX Oncology by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares in the last quarter. AQR Capital Management LLC lifted its stake in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares during the last quarter. SG Americas Securities LLC boosted its holdings in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in ALX Oncology in the second quarter valued at approximately $63,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Stock Performance

Shares of ALXO stock opened at $1.62 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04. The firm’s 50 day moving average price is $1.52 and its 200-day moving average price is $3.00. ALX Oncology has a one year low of $1.19 and a one year high of $17.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.